BASF and Poietis sign an agreement on 3D bioprinting

©Poietis

BASF and Poietis have announced the signature of a framework agreement on further development and services in the field of 3D bioprinting technology. The main goal is to further improve the 3D laser-assisted bioprinted skin models that have been co-developed since 2015 to evaluate cosmetic ingredients for skin care applications.

The 3D laser-assisted bioprinting technology, by which organic tissues can be reproduced, allows a precise positioning of skin cells in three-dimensional structures. Thus, it is now possible to produce fully printed skin equivalents in only two weeks to further study active ingredients effectiveness.

BASF intends to develop and market several active ingredients for cosmetic products that harness the findings of the collaboration. At this year’s Cosmetagora, Dermagenist™ led the way being BASF’s first active ingredient whose efficacy has been confirmed by using laser-assisted bioprinted skin models.